Recruiting studies: Acral Melanoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06961357 Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Phase 3 · 82 location(s) · Immunocore Ltd · NCT05549297 Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
Phase 3 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT05789043 Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210 Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
Phase 2 · 4 location(s) · Fudan University · NCT06965231 Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
Phase 2 · 1 location(s) · Di Wu · NCT04331093 A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692 The Registry Study of Genetic Alterations of Melanoma in Taiwan
Phase N/A · 16 location(s) · National Health Research Institutes, Taiwan · NCT06952400 Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024 Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT05512481 Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
Phase 2 · 2 location(s) · Emory University · NCT07155317 TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 · 41 location(s) · Tizona Therapeutics, Inc · NCT04485013 A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectabl
Phase 2 · 31 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06797297 A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V60
Phase 2 · 331 location(s) · SWOG Cancer Research Network · NCT04511013

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.